Silence Therapeutics plc

US$19.73As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:SLNHealthcare
Country USA
PE (Fwd) •••
TSR 6Y CAGR 2.17%
Div yield —
ROE (90.41%)
Biotechnology
Beta (5Y) 1.34
PE TTM —
TSR TTM 175.56%
Mkt cap US$1.188B
ROIC (60.67%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$21
8.11%
(53.66%)
Hold 6|10|5|8|4
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.35
0.38
0.36
0.39
(2.31%)
3.54%
0.64%
9.45%
Revenue$M
91.13
90.43
92.33
95.42
1.12%
(3.26%)
(0.42%)
2.18%
Peers (US$1.188B)
Cap (US$)
PE
2.071B
5.627x
1.189B
—
Capital
TTM
5Y
10Y
Leveragex
1.060
0.033
0.033
EBIT/Intx
0.070
0.544
0.497
Own earn%
(23.57)
12.92
9.93
Sh yield%
45.68
33.58
31.38
Owners
Insiders/Inst%
13.14
66.90
Short interest%
5.19
SBC / revenue%
1.69
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
9
Op margin range%
13–17
$1 testx
—
Incr. ROIC%
2